Physician profile
Sandra Ferraz
NPI 1265026272
$8,421.90
in general payments reported to CMS, 2019-2025
30 companies · $2,628 in 2025
The $2,628 reported for 2025 was more than what 96% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $524 · 2023: $3,205 · 2024: $2,064 · 2025: $2,628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,799 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,798.61 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,751.86 | 2022-2025 | |
| Janssen Biotech, INC. | $1,121.76 | 2022-2025 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $744.86 | 2023-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $604.68 | 2023-2025 | Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $599.05 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Ardelyx, INC. | $542.65 | 2023-2025 | Ibsrela |
| Novo Nordisk INC | $270.77 | 2023-2025 | Wegovy |
| Pfizer INC. | $257.15 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $245.53 | 2023-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $241.21 | 2024-2025 | Voquezna |
| Braintree Laboratories, INC. | $201.35 | 2022-2025 | Sutab, Suflave |
| Aimmune Therapeutics, INC. | $196.81 | 2023-2025 | Vowst, Zenpep |
| Intercept Pharmaceuticals, INC. | $167.59 | 2023-2025 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $148.61 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $135.56 | 2022-2024 | Rebyota |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $134.05 | 2022-2024 | Zeposia |
| Lilly USA, LLC | $133.38 | 2023-2025 | Omvoh |
| Janssen Scientific Affairs, LLC | $125.00 | 2022 | |
| Madrigal Pharmaceuticals | $123.18 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $119.12 | 2024-2025 | Sucraid, Sucraid |
| E.R. Squibb & Sons, L.L.C. | $117.69 | 2023 | |
| Amgen INC. | $92.22 | 2022-2023 | Avsola, Amjevita |
| Celltrion USA INC. | $90.17 | 2024-2025 | Vegzelma |
| Genzyme Corporation | $57.02 | 2023 | |
| Daiichi Sankyo INC. | $44.87 | 2023 | Injectafer |
| Organon LLC | $39.07 | 2023 | Renflexis, Hadlima |
| Merck Sharp & Dohme LLC | $34.47 | 2022-2024 | Dificid |
| Orphalan INC | $32.34 | 2024 | Cuvrior |
| Regeneron Healthcare Solutions, INC. | $27.53 | 2023 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.35 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Ferraz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.